Business Model Breakdown
How BWX Technologies Inc Makes Money
BWXT
Market Cap
$17.1B
Annual Revenue
$3.4B
Profit Margin
10.2%
The Short Version
BWX Technologies designs, manufactures, and services nuclear components and provides nuclear fuel to critical government entities and commercial customers. Its primary business is supplying nuclear propulsion systems for the US Navy's submarines and aircraft carriers. The company is also a leading developer of Small Modular Reactors (SMRs) for both defense applications and commercial power generation, and produces specialized medical isotopes for diagnostic and therapeutic uses. Essentially, it leverages its deep expertise in nuclear technology to serve national security, energy, and healthcare sectors.
Where the Revenue Comes From
Naval Nuclear Propulsion (~60-70% of revenue)
Nuclear Power (SMR development, fuel fabrication, services) (~20-30% of revenue)
Medical Isotopes (growing, ~5-10% of revenue)
Who buys: US government (Department of Defense, Department of Energy), commercial nuclear power companies, medical and pharmaceutical sectors.
Why It Works (Competitive Advantages)
- ✔Proprietary nuclear technology and deep domain expertise.
- ✔Sole provider status for critical US Navy nuclear propulsion components, creating an unbreakable government-backed moat.
- ✔High regulatory barriers to entry in the nuclear sector.
- ✔Strong relationships and trust with government agencies (DoD, DOE).
Economic Moat: Wide (Intangible Assets/IP, Switching Costs, Efficient Scale, Government Relationships/Licenses)
What Our Analysis Says
DVR Score as of June 9, 2026
BWX Technologies maintains a powerful market position in specialized nuclear technologies, including naval propulsion, SMRs, and medical isotopes, underpinned by an unassailable moat and strategic government partnerships. However, the mandate for a 10x return within 3-5 years from an already large-cap company ($17.17B) remains exceedingly challenging. The nuclear industry is characterized by capital intensity, long development cycles, and heavy regulatory oversight, which inherently limits the pace of exponential growth required for such a return. While there is growth potential in SMRs and medical isotopes, these are long-term plays that are unlikely to generate the necessary hyper-growth within the specified timeframe from the current valuation. The recent insider sale, though pre-arranged, does not signal a strong conviction in massive near-term upside. Much of BWXT's strong long-term outlook appears to be adequately priced into its current valuation.